

# Long noncoding RNAs, glucose metabolism and cancer (Review)

XIN-RUI HOU<sup>1,2</sup>, ZHEN-DONG ZHANG<sup>1,2</sup>, XIAO-LAN CAO<sup>1,2</sup> and XIAO-PING WANG<sup>2,3</sup>

<sup>1</sup>Graduate School; <sup>2</sup>Key Laboratory of High Altitude Hypoxia Environment and Life Health;

<sup>3</sup>School of Medicine, Xizang Minzu University, Xianyang, Shaanxi 712082, P.R. China

Received March 6, 2023; Accepted June 8, 2023

DOI: 10.3892/ol.2023.13925

**Abstract.** Cancer is a serious and potentially life-threatening disease, which, despite numerous advances over several decades, remains a challenge to treat that challenging to detect at an early stage or treat during the later stages. Long noncoding RNAs are >200 nucleotides long and do not possess protein-coding capacity, instead regulating cellular processes, such as proliferation, differentiation, maturation, apoptosis, metastasis, and sugar metabolism. Several studies have shown the role of lncRNAs and glucose metabolism in regulating several key glycolytic enzymes and the activity of multiple functional signaling pathways during tumor progression. Thus, it is possible to further learn about the effects of lncRNA and glycolytic metabolism on tumor diagnosis, treatment, and prognosis through a thorough investigation of the lncRNA expression profiles and glycolytic metabolism in tumors. This may provide a novel strategy for improving the management of several types of cancer.

## Contents

1. Introduction
2. The role of lncRNA and glycometabolism in digestive tract tumors
3. The role of lncRNA and glucose metabolism in other tumors
4. Conclusions and future perspectives

## 1. Introduction

Long noncoding RNAs (lncRNAs), sometimes known as competitive endogenous RNA (ceRNA), are a class of noncoding RNAs that are >200 nucleotides in length, which are

involved in multiple cellular processes, such as proliferation, differentiation, maturation, apoptosis, metastasis, and metabolism (1-3). By targeting complementary miRNAs, ceRNAs can downregulate miRNA expression, indirectly regulating the expression of the downstream mRNA and thus affecting the behavior of a tumor cell (4). lncRNAs can bind to DNA, RNA, and proteins to form complexes that regulate transcription (5). A diseased state is ultimately brought on via the regulation of gene expression via various mechanisms, including mRNA stability and translation (6-8). It has been shown that lncRNAs can be categorized into different classes, which modulate tumor activity through differing functions. For example, they act as molecular sponges for miRNAs (9), modifiers and decoys for ribosomal proteins or ribonucleic acids (10), catalysts for gene transcription (11), gene methylation (12), protein kinase phosphorylation (13), and stabilizers of protein expression (14). lncRNAs can also act as coactivators of signaling factors as agonists. Additionally, they may alter the formation of tumors by sensitizing or desensitizing the cancerous cells to chemotherapeutic drugs. For example, the lncRNA LINC02525, which acts as a modifier of ribosomal proteins, can function as an oncogene by interacting with the ribosomal protein RPL35 to activate the translation of E2F1 and subsequently enhance the transcription of the GTPase-activating protein DEPDC1B to regulate the biological activity of neuroblastoma (NB) cells (15). Additionally, lincRNA-p21 acts as a gene transcription catalyst by mediating the binding of hnRNPK to promote transcription of its neighboring gene, cyclin-dependent kinase inhibitor 1A (*CDKN1A*), which encodes p21, and mediates the binding of hnRNPK to it, negatively regulating mRNA translation (10). lncRNAs can influence the transcription of genes on several chromosomes and can also be used as a decoy to trigger protein and RNA regulation (16). LINC00184 increases protein kinase phosphorylation and gene methylation, which increases the level of glycolysis in esophageal cancer (EC) cells by promoting *PTEN* methylation and *AKT* phosphorylation (17). Through the LINRIS/*IGF2BP2*/v-Myc avian myelocytomatosis viral oncogene homolog (*c-Myc*) axis, the lncRNA LINRIS can stabilize protein expression, prevent *IGF2BP2* degradation, and upregulate *Myc* expression to maintain glycolysis in colorectal cancer (CRC) cells (12). It was found that the *SNP rs11672691* risk allele at the regulatory region 19q13 locus upregulated the expression of transcription factors NK3 homeobox 1 (*NKX3.1*), Yin-Yang 1 (*YY1*), PCAT19-long through promoter-enhancer switching bifunctional regulatory elements in the SNP region, increased the

---

*Correspondence to:* Professor Xiao-Ping Wang, School of Medicine, Xizang Minzu University, 6 Wenhui East Road, Weicheng, Xianyang, Shaanxi 712082, P.R. China  
E-mail: xpwang@xzmu.edu.cn

**Key words:** long non-coding RNA, tumors, biomarkers, glucose metabolism, therapy, competing endogenous RNA

expression of HNRNPAB-PCAT19-long ribonucleoprotein complex and cell cycle gene expression (18). Increased levels of the transcription factor homeobox A2 (*HOXA2*) and the carcinoembryonic antigen-related cell adhesion molecule 21 (*CEACAM21*) are also brought on by prostate cancer-associated transcript 19 (PCAT19) upregulation, which together promote prostate cancer (PCa) invasion (13,18). As a desensitizer of tumor-resistant cells, lncRNA differentiation antagonizing non-protein coding RNA (DANCR) exerts a sponging effect through the miR-125b-5p/hexokinase (HK)2 axis to down-regulate miR-124b-5p expression and thus enhances HK2 activity, desensitizing cisplatin-resistant CRC cells, while silencing DANCR exhibits the opposite effect, decreasing the resistance of CRC cells to cisplatin (9). LINC00504 functions as a coactivator of *c-Myc* and stimulates CRC glucose metabolism levels by increasing the recruitment of *c-Myc* to chromatin sites, which is how chromatin modifiers are used to modulate gene transcription (11). lncRNAs can regulate tumor apoptosis by affecting chromosomal gene transcription, post-transcription and the regulation of epigenetic mechanisms such as gene methylation, which results in lncRNAs acting as tumor suppressors or oncogenes, which provides new potential targets for improving tumor prognosis and metastasis (19).

The three primary metabolic pathways are glycolysis, pentose phosphate, and oxidative phosphorylation, of which, glycolysis is highly active in tumor cells (20). Otto Warburg, a German scientist, discovered the Warburg effect in the 1950s, which states that when oxygen levels are adequate, tumor cells do not undergo oxidative phosphorylation like normal cells but instead produce the required energy by aerobic glycolysis (21). A complex process of glucose metabolism in neoplastic cells contributes to the dysregulated lncRNA expression profiles in neoplasms. Regulation via lncRNAs can alter gene transcription levels, protein synthesis, and translation rates, affecting glucose metabolism in tumor cells. Several studies have been conducted to assess the specific molecular mechanisms of lncRNAs in tumor glucose metabolism. In these studies, it was found that a single lncRNA can exert a regulatory role in several types of cancer, often have differing effects. For example, potassium voltage-gated channel subfamily Q member 1 opposite strand/antisense transcript 1 (*KCNQ1OT1*) can promote the glycolysis of CRC cells through HK2 (22); in contrast, it can also compete with miR-34c-5p to increase aldolase A (*ALDOA*) activity and glycolysis levels in osteosarcoma (OS) cells (23). Similarly, LINC00504 increases glycolysis in ovarian cancer (OC) (24) and CRC (11) by increasing the activity of the glycolytic enzymes HK2, pyruvate dehydrogenase kinase 1 (PDK1), pyruvate kinase 2 (PKM2), and the expression levels of *c-Myc* in the corresponding tumor cells. In pituitary tumors (PT), urothelial cancer associated 1 (*UCA1*) accelerates HK2 and lactate dehydrogenase A (*LDHA*) activation to increase glycolysis (25). At the same time, in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) (26), *UCA1* and HK2 expression are negatively correlated. It was found that several lncRNAs can regulate a single gene to influence tumor progression. *MYC* genes have a significant impact on the regulation of transcription. lncRNA *GLCC1* (27) and LINC00504 (11) can regulate *c-Myc* to promote glycolysis of tumor cells and accelerate tumor growth, whereas LINC00261 (28) is negatively correlated

with *c-Myc*. With MIR17HG being significantly upregulated in CRC (29) while acting as a tumor growth suppressor in OC (30), the effect of lncRNA expression varies in different tumors. As shown in Fig. 1, it was found that lncRNAs, including protein tyrosine phosphatase receptor type G antisense RNA 1 (PTPRG-AS1) (31), H19 (32), MIR210 host gene (MIR210HG) (33), MIR17HG (29), LINC00243 (34), and LINC00346 (35), promote the growth of tumor cells, altering the expression of key gluconeogenesis enzymes through sponging of miRNAs. Additionally, several signaling molecules are regulated by lncRNAs, such as transmembrane protein 161B antisense RNA 1 (TMEM161B-AS1) (36), high expression in hepatocellular carcinoma (HEIH) (37), lncENST (38), and LINC00261 (28), that can affect glycolysis and tumor cell activity (Fig. 2). The effects of lncRNAs and glycometabolism in cancer are summarized in this review.

## 2. The role of lncRNA and glycometabolism in digestive tract tumors

The majority of malignant tumors occur in the digestive system, which includes the esophagus, the stomach, the liver, the pancreas, and the colon (39). Their characteristics of slow diagnosis, challenging treatment, poor prognosis, and high mortality rates have become significant clinical issues that must be resolved. Numerous studies have shown that lncRNAs can target key enzymes and various signaling factors that affect glycolysis and are crucial for regulating digestive system tumor expression.

*The role of lncRNA and glucose metabolism in EC.* EC is a common, aggressive, malignant tumor with a poor prognosis worldwide. An ever-increasing number lncRNAs are being reported to be involved in the progression of EC. However, more research is required on lncRNAs and their potential molecular mechanisms for regulating EC glucose metabolism.

*lncRNA and key glycolytic enzymes regulate EC glucose metabolism.* A recent study found that PTPRG-AS1 upregulated PDK1 expression through a PTPRG-AS1/miR-599/PDK1 axis via sponging miR-599 (31), thereby promoting EC cell proliferation, migration, and glycolysis. The lncRNA actin  $\gamma$  1 pseudogene (AGPG) is a novel stimulator of glycolysis and tumorigenesis. It regulates 6-phosphofructose-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), negatively regulated by the P53 oncogene to enhance sugar metabolism and promote the progression of the cell cycle. Future treatments for EC may be tailored using AGPG, which targets an AGPG/P53/PFKFB3 axis (40).

*lncRNA and signal molecules regulate EC glucose metabolism.* It was found that LINC00184 could promote *PTEN* methylation and *AKT* phosphorylation by regulating the *PTEN/Akt* axis, subsequently promoting glycolysis and oxidative phosphorylation of mitochondria from EC cells (17). Upregulated expression of TMEM161b-AS1 improved patient's prognosis. The TMEM161B-AS1/miR-23a-3p/hypoxia-inducible factor 1 subunit  $\alpha$  inhibitor (*HIF1AN*) signaling axis offers a new alternative direction for the targeted treatment of ECs. It was shown that miR-23a-3p uptake by TMEM161B-AS1 was to enhance the expression of *HIF1AN* by inhibiting HK2, phosphofructokinase isoform (PFKM), LDHA, and *HIF1A* thereby attenuating EC reproduction, invasion, and glycolysis (36).




Figure 1. Schematic representation long noncoding RNA-mediated regulation of tumor glycolysis via enzymes. PTPRG-AS1, protein tyrosine phosphatase receptor type G antisense RNA 1; PDK1, pyruvate dehydrogenase kinase 1; H19, herein 19; LDHA, lactate dehydrogenase A; TUG1, taurine upregulated 1; HK2, hexokinase 2; PKM2, pyruvate kinase 2; GLUT1, glucose transporter type 1; PVT1, plasmacytoma transformation migration gene 1; HOXB-AS3, homeobox B antisense RNA 3; SNHG14, small nucleolar RNA host gene 14; UCA1, urothelial cancer associated 1; PDIA3P, protein disulfide isomerase family A member 3 pseudogene 1; G6PD, Glucose-6-phosphate dehydrogenase; EC, esophagus cancer; GC, gastric cancer; HCC, hepatocellular carcinoma; PC, pancreatic cancer; CRC, colorectal cancer; NSCLC, Non-small cell lung cancer; BRCA, invasive breast carcinoma; OS, osteosarcoma; OC, ovarian cancer; GBMLGG, glioma; PT, pituitary tumor; MEL, melanoma; OSCC, oral squamous cell carcinoma; MM, multiple myeloma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma.

*The role of lncRNA and glucose metabolism in gastric cancer (GC).* GC is ranked the fifth most common type of cancer worldwide and the third leading cause of death in patients with high cancer risk. Most patients with GC have a poor survival rate, with a tendency for their 5-year survival rate to be <50% (41).

*lncRNA and key glycolytic enzymes regulate GC glucose metabolism.* Sun *et al* (32) found that lncRNA H19 promotes GC cell proliferation by regulating a miR-519d-3p/LDHA axis and promoting glycolysis. Pei *et al* (42) found that small nucleolar RNA host gene (SNHG) 7 was upregulated in GC cisplatin-resistant cells that were resistant to cisplatin, and that knocking down SNHG7 could successfully inhibit the expression of LDHA and sensitize cisplatin-resistant cells. miR-34a is negatively correlated with SNHG7, which can target LDHA and knockdown lncRNA to downregulate the expression of cisplatin-resistant GC cells and inhibit GC glucose metabolism. As a result, SNHG7 can reduce the sensitivity to cisplatin in GC cells through a miR-34a/LDHA axis. Similarly, Hu *et al* (43) showed that lncRNA HAGLR desensitizes GC5-Fu-resistant cells by inhibiting the miR-338-3p/LDHA-glycolytic axis via sponging. Qian *et al* (44) found that the lncRNA distal-less homeobox six antisense RNA 1 (DLX6-AS1) may target and

precisely promote GC glycolysis through direct contact with miR-4290 and PDK1, enhancing its malignant biological activity. Deng *et al* (45) showed that LINC00242 could regulate the miR-1-3P/Glucose-6-phosphate dehydrogenase (G6PD) axis and promote the glycolytic effect of GC. Recent studies have found that the expression of lncRNA VAL was significantly higher in GC, indicating a poor prognosis. Biological function tests showed that VAL promoted the rapid progression of GC. The direct binding of VAL to PKM2 increases PKM2 kinase activity, promoting glycolysis in GC cells. Additionally, it can inhibit PKM2 from interacting with Parkin and inhibits the glycation of PKM2 (46). The lncRNA muscle layer antisense RNA 1(MSC-AS1) promotes GC cell proliferation and glycolysis by enhancing the expression of PFKFB3 (47).

*lncRNA and signal molecules regulate GC glucose metabolism.* Xu *et al* (48) reported that lncRNA heart and neural crest derivatives expressed two antisense RNA 1 (HAND2-AS1) inhibited the activity of a lncRNA HAND2-AS1/miR-184/HIF3A signaling axis in gastric adenocarcinoma (AGS) tissues and cells, which in turn down-regulated hypoxia-induced AGS glycolysis. Qian *et al* (49) found that LINC01391 inhibits GC invasion, migration,




Figure 2. Schematic representation of long noncoding RNA-mediated regulation of tumor glycolysis via various signaling molecules. TMEM161B-AS1, transmembrane protein 161B antisense RNA 1; HIF1AN, hypoxia inducible factor 1 subunit alpha inhibitor; PFKM, phosphofructokinase isoform; HK2, hexokinase 2; LDHA, lactate dehydrogenase A; HEIH, high expression in hepatocellular carcinoma; STAT3, signal transducer and activator of transcription 3; Nkx2-5, homeobox protein Nkx-2.5; ERK, extracellular regulated protein kinases; HIPK2, homeodomain-interacting protein kinase 2; IGF2BP1, insulin-like growth factor 2 mRNA-binding proteins 1; ASMTL-AS1, acetylserotonin O-methyltransferase like antisense RNA 1; FOXO1, forkhead box O1; FAM83A-AS1, sequence similarity family 83 member A-antisense ribonucleic acid 1; HIF1A, hypoxia inducible factor 1 subunit alpha; HNF4A-AS1, hepatocyte nuclear factor 4 alpha antisense RNA 1; CTCF, CCCTC-binding factor; Wnt5a, Wnt family member 5A; Ror2, receptor tyrosine kinase like orphan receptor 2; TRIM44, tripartite motif 44; PFKFB2, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2; CAF, Cancer-associated fibroblasts; CXCL14, C-X-C motif chemokine 14; EC, esophagus cancer; GC, gastric cancer; HCC, hepatocellular carcinoma; PC, pancreatic cancer; PTC, papillary thyroid carcinoma; LUAD, lung adenocarcinoma; NB, neuroblastoma; OS, osteosarcoma; CRC, colorectal cancer; OC, ovarian cancer.

and aerobic glycolysis by targeting a miR-12116/CKLF-like MARVEL transmembrane domain containing 2 (*CMTM2*) axis after downregulating miR-12116 expression and upregulating the effect of *CMTM2* expression. Yan *et al* (50) found that insulin growth factor 2 antisense (*IGF2-AS*) gene knockout could inhibit glycolysis and promote apoptosis of GC cells through its sponging effect. It was also revealed that the *IGF2-AS* absorbed miR-195 to inhibit the expression of cAMP-responsive element binding protein 1 (*CREB1*). Additionally, it has been found that miR-506 can target *STAT3* expression and inhibit GC cell occurrence and progression. LncRNA-nuclear paraspeckle assembly transcript 1 (*NEAT1*) and miR-506 are negatively correlated. Through the *NEAT1*/miR-506/*STAT3* axis, the endogenous *NEAT1* sponge can promote the progression of GC cells and glucose metabolism after absorbing miR-506 (51). Similarly, miR-4500 absorption by *HEIH* sponges inhibits *STAT3*-mediated autophagy and promotes the progression of GC malignancy and glycolysis (37). Sun *et al* (52) showed that *LINC00152* downregulates miR-139-5p in GC cells. Since miR-139-5P inhibits glycolysis in GC cells by suppressing the expression of

AMP-activated  $\alpha 1$  catalytic subunit (*PRKAA1*), *LINC00152* promotes *PRKAA1* by upregulating miR-139-5P expression to accelerate glycolysis in GC cells via a sponging effect. Li *et al* (53) found that paeonol may inhibit the expression of *LINC00665* and mitogen-activated protein kinase 1 (*MAPK1*) expression via the *LINC00665*/miR-665/*MAPK1* axis, preventing the proliferation, migration, invasion, and glycolysis of apatinib-resistant GC cells while promoting apoptosis.

*The role of lncRNA and glucose metabolism in hepatocellular carcinoma (HCC).* HCC is among the most prevalent malignancies worldwide, particularly in East Asia and Africa. The high prevalence of these diseases is caused by the lack of monitoring and treatment options (54). Below is a summary of recent research on the role of lncRNA in regulating aerobic glycolysis in HCC.

*lncRNAs and key glycolytic enzymes regulate glucose metabolism in HCC.* PKM2 was found to be essential, and E2F1-activated SNHG1 regulates the miR-326/PKM2 axis to promote PKM2 expression, glycolysis, and HCC cell proliferation (55). The orphan nuclear receptor Nur77 regulates

the Nur77-WFDC21P-PFKP/PKM2 axis by transcriptionally activating the lncRNA WAP four-disulfide core domain 21 pseudogenes (WFDC21P), which suppresses PFKP and PKM2 and impedes HCC glycolysis (56). LDHA and PKM2 are more readily bound to the fibroblast growth factor receptor type 1 by the lncRNA highly upregulated in liver cancer (HULC), resulting in their phosphorylation and facilitating glycolysis (57). By inhibiting forkhead box M1 (*FOXM1*) transactivation through *STAT3* and regulating glucose transporter Type 1 (GLUT1) by competing with *STAT3*, lncRNA SLC2A1-AS1 deactivates HCC cells by interfering with the *FOXMI/*GLUT1 axis and inhibits aerobic glycolysis in HCC cells (58). *AMPK $\beta$ 2*, a downstream marker gene of miR-455-3P, was found to be downregulated to stimulate the enzymatic protein activity of HK2, and TUG1 was found to activate HK2 and promote cell proliferation, metastasis, and glycolysis by upregulating the expression of miR-455-3p through the TUG1/miR-455-3p/*AMPK $\beta$ 2* axis (59). The inactivation of GLUT1 and HK2, caused by genistein-induced downregulation of *HIF1A*, promotes the apoptosis of HCC aerobic glycolytic cells and the antitumor effect of sorafenib on HCC cells (60). According to a study, aspirin can target the inhibition of aerobic glycolysis and PFKFB3 overexpression in HCC cells, sensitizing sorafenib-resistant HCC cells. The findings provide a strong theoretical basis for the targeted treatment of sorafenib-resistant HCC cells and the eradication of HCC cells with aspirin and sorafenib (61).

*lncRNAs and signaling molecules regulate glucose metabolism in HCC.* A previous study reported that the Warburg effect is mediated by human epidermal growth factor receptor (*ErbB*) 2, which activates heat shock factor 1 before upregulating LDHA (62). Its promoter may interact negatively with the transcription factor *Nkx2-5*. Inhibiting the Warburg effect in HCC cells, lncENST directly binds to and activates the transcription factor *Nkx2-5* through an *Nkx2-5/ErbB2* axis. This inhibits *ErbB2* gene transcription and downregulates *ErbB2* protein expression (38). HOX transcript antisense RNA (HOTAIR) regulates a miR-130a-3p/*HIF1A* axis on miR-130a-3p uptake, resulting in high expression of *HIF1A*, which inhibits glycolysis in hypoxia-induced HCC cells (63). Regulating GSK3 $\beta$  and Wnt/ $\beta$  catenin signaling and promoting HCC, SNHG5 promoters (64). In HCC cells, lncRNA cyclin-dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1) sponge let-7c-5p promotes upregulation of nucleosomal assembly protein 1 like 1SS-mediated *PI3K/Akt/mTOR* axis-stimulated glycolysis (65). While NEAT1 is the primary transcriptional target of *mTOR*, it can also control the lncRNA transcriptome in HCC. When activated in cancer, *mTORC1* inhibits NEAT1\_2 expression while facilitating mRNA splicing and the expression of key glycolytic enzymes, which promotes HCC glucose metabolism and cell proliferation (66). By controlling the *MAPK/extracellular regulated protein kinases (ERK)* pathway, hypoxia-inducible lncRNA neuropeptide S receptor 1 antisense RNA 1 was also found to promote the proliferation and glycolysis of HCC cells (67). The target gene of the lncRNA Fiveprime to Xist (FTX) is the peroxisome proliferator-activated receptor  $\gamma$  (*PPAR $\gamma$* ), and FTX functions downstream of *PPAR $\gamma$* . Through overexpression of the FTX/*PPAR $\gamma$*  axis, FTX promotes activation of the *PPAR $\gamma$*  pathway, which attenuates the expression

of tumor necrosis factor- $\alpha$  (TNF $\alpha$ ), leptin, and PDK1, regulating GLUT4, PDK1, and PFKL in HCC cells, and maintains increased glycolysis in HCC (68). Additionally, the progression of HCC may be aided by the regulation of Bcl-2-related protein A1 (*BCL2A1*) expression by the lncRNA POU3F3 adjacent noncoding transcript 1 (PANTR1) via sponging of miR-587 (69).

*The role of lncRNAs and glucose metabolism in pancreatic cancer (PC).* PC is a highly lethal malignancy that is often diagnosed in the first instance as advanced PC, and thus has a poor prognosis, with an overall 5-year survival rate of <6% (70,71). By 2030, PDAC is predicted to be the second leading cause of cancer-related death, and is refractory to most current treatment strategies (72). There are few functional targets identified for the management of PC and their underlying mechanisms remain to be determined. The following is a summary of the known findings.

*lncRNAs and key glycolytic enzymes regulate PC glucose metabolism.* The lncRNA MIR210HG was found to be upregulated in PC and is a key oncogenic regulator of PC invasiveness and glycolysis. Through the MIR210HG/miR-125b-5p/HK2/PKM2 axis, MIR210HG and miR-125b-5p bind competitively to target HK2/PKM2 expression, enhancing PC cell invasion and glycolysis (33).

*lncRNAs and signaling molecules regulate PC glucose metabolism.* According to recent studies, homeodomain-interacting protein kinase 2 (*HIPK2*) inhibits PC glycolysis through the *ERK/c-Myc* signaling pathway. At the same time, LINC00261 activates the *HIPK2/ERK* pathway through the sponging of miR-222-3P and blocking *IGF2BP1* from inhibiting *c-Myc*-mediated glycolysis, which inhibits PC cell proliferation (28). lncRNA-targeted regulation of PC drug resistance continues to be a significant clinical challenge. It has been found that the lncRNA (*HIF1A-AS1*) induces Y box-binding protein 1 (YB1) phosphorylation and translation activation of *HIF1A* through the *HIF1A-AS1/HIF1A* axis, desensitizing gemcitabine-resistant PC cells and promoting aerobic glycolysis, providing an efficient target for GEM therapy (73).

*The role of lncRNA and glucose metabolism in CRC.* CRC is one of the most prevalent cancers of the digestive system worldwide, the fourth most common form of cancer in the United States, after breast cancer, lung cancer, and PCa, and the second leading cause of cancer-related death, after lung cancer, in terms of cancer mortality worldwide (74,75). Meanwhile, in the 21st century, CRC is rising in the cancer spectrum and is in the top five of the most common cancers in China (76). Patients with CRC have a 5-year overall survival rate of ~64% (74). Several studies have shown that lncRNAs and glucose metabolism significantly impact colon cancer development, progression, and outcomes.

*lncRNAs and key glycolytic enzymes regulate CRC glucose metabolism.* The activity of key enzymes such as HK1 (29), HK2 (77), PKM1 (78), and PKM2 (14) are crucial for glucose metabolism in CRC cells. Poor survival is correlated with high MIR17HG expression. In CRC cells, MIR17HG as a ceRNA binds miR-138-5p to regulate the expression of HK1, resulting in glycolysis, aggressive cell behaviors, and CRC liver metastasis. The *p38/ELK-1* axis

is subsequently activated by lactic acid accumulated during glycolysis. The transcriptional expression of MIR17HG from CRC cells, thus, continuously enhances CRC progression (29). Additionally, HK1 can be promoted by the interaction between lncARSR and miR-34a-5p to increase the aerobic glycolysis of CRC (79). KCNQ1OT1 and HK2 expression are positively correlated. Overexpression of KCNQ1OT1 upregulates HK2 protein expression at the post-transcriptional level, which increases aerobic glycolysis and cell proliferation in CRC (22). Similarly, lncSLCC1 increases HK2 expression. The risk allele *SNP rs6695584* promotes lncSLCC1 expression by interacting with the transcription factor BATF and upregulated lncSLCC1 interacts with aryl hydrocarbon receptor to transcriptionally activate HK2 expression to promote CRC progression (77). Additionally, miR-125b-5p was targeted to regulate HK2 to inhibit CRC progression and was negatively correlated with lncRNA DANCR. Through competitive inhibition of the HK2 3'-UTR by a miR-125b-5p/HK2 axis, endogenous DANCR was targeted by miR-125b-5p, desensitizing cisplatin-resistant cells and thus increasing glycolysis (9). It was found that the lncRNA HOXB-AS3 encodes a 53-amino acid polypeptide that inhibits the production of PKM, which hnRNP A1 mediates, and thereby aerobic glucose metabolism in CRC (78). By binding to PKM2 and increasing protein stability, Fez family zinc finger protein 1 antisense ribonucleic acid 1 (FEZF1-AS1) promotes PK activity and lactate production. Additionally, *STAT3* expression is disrupted by down-regulated FEZF1-AS1, which has an impact on downstream proteins (14). lncRNAs have been shown to promote the progression of CRC by increasing the PKM2/PKM1 ratio. If SNHG6 is upregulated in CRC, SNHG6-induced hnRNPA1 specifically splices PKM mRNA, increasing the PKM2/PKM1 ratio and enhancing aerobic glycolysis in CRC cells (80). Similarly, miR-137 attenuates glycolysis in CRC cells. It sensitizes 5-FU/cisplatin-resistant cells by blocking PKM conversion from PKM1 to PKM2. However, miR-137 binding and inhibition by the lncRNA X-inactive-specific transcript (XIST) blocks PKM2 to PKM1 conversion through an XIST/miR-137/PKM axis, which increases the PKM2/PKM1 ratio and enhances glycolysis and chemotherapy resistance in CRC (81). It has been demonstrated that traditional Chinese medicines can regulate lncRNA and key glycolysis enzymes, exerting an antitumor effect. In millet bran, ferulic acid (FA) and p-coumaric acid (P-CA) have anti-cancer properties and can synergistically inhibit tumor growth. lncRNA 495810 positively regulates PKM2. A candidate way for nutritional intervention and treatment of CRC is provided by FA and P-CA, which inhibit lncRNA 495810 and PKM2 to block aerobic glycolysis in CRC (82).

*lncRNAs and signaling molecules regulate CRC glucose metabolism.* By regulating a *HIF1A*/pituitary tumor transformation 3 pseudogene (PTTG3P)/*YES1* associated transcriptional regulator (*YAPI*) axis, the lncRNA PTTG3P has been found to increase macrophage proliferation, glycolysis, and M2 polarization (83). LINC00265 sponging inhibits miR-216B-5P, which in-turn promotes CRC glycolysis by increasing the expression of tripartite motif 44 (*TRIM44*) through regulation of a miR-216B-5P/*TRIM44* axis (84). Similarly, miR-20b-5p is sponged by collagen type IV  $\alpha 2$  chain antisense RNA 1

(COL4A2-AS1) to increase *HIF1A* expression, promoting CRC cell proliferation and glycolysis (85). CRC cells cannot exist without *Myc* oncogene-mediated signaling pathways. For example, the lncRNA LINRIS stabilizes *IGF2BP2* to prevent *IGF2BP2* degradation, which can maintain *Myc*-mediated glycolysis through a LINRIS/*IGF2BP2*/*Myc* axis and support the *in vitro* and *in vivo* proliferation of CRC cells (12). Heat shock protein 90 (HSP90)-binding lncRNA GLCC1 stimulates aerobic glycolysis of CRC cells by stabilizing *c-Myc* protein through a GLCC1/*c-Myc*/LDHA axis and thus increasing the expression of LDHA (27). The *c-Myc* coactivator LINC00504 increases *c-Myc* recruitment to chromatin sites and increases *c-Myc* transcriptional activation to increase CRC glucose metabolism levels. LINC00504 functions in the pentose phosphate pathway (PPP), which produces nicotinamide adenine dinucleotide (NADPH) to induce redox reactions, increasing the supply of energy for cell growth, and increasing citrate levels. In addition to promoting glycolysis, LINC00504 also promotes G6PD activity. Expression of enzymes of the PPP, glucose absorption, glycolysis, and the tricarboxylic acid (TCA) cycle is promoted by LINC00504, which is a key gene regulator for enhancing glucose metabolism in CRC (11). RAD51-AS1 sponges miR-29b/c-3p to indirectly upregulate N-myc downstream-regulated gene 2 (*NDRG2*) expression, thus impeding CRC cell progression (86). It was also shown that sponging of miR-874-3P by MCF2L-AS1 increased the expression of *FOXM1* through a miR-874-3P/*FOXM1* axis, promoting CRC cell growth, invasion, and glycolysis (87). Additionally, through a miR-124/MyO6 axis and miR-188/TAB3 axis, respectively, HNF1A-AS1 and ZEB2-AS1 facilitate CRC cell migration, invasion, and glycolysis (88,89). A significant clinical issue in CRC is oxaliplatin (L-OHP) resistance. According to certain research, lncRNAs can encode proteins that subtly contribute to CRC resistance. The lncRNA-AP-encoded short peptide PEP-AP can decrease PPP activity, sensitize L-OHP-resistant CRC, and prevent the expression of transaldolase 1 (TALDO1). As a result, PEP-AP could be considered as a sensitizer for individualized treatment of L-OHP-resistant CRC (90).

### 3. The role of lncRNA and glucose metabolism in other tumors

lncRNAs are crucial for regulating glucose metabolism in several types of cancer, including thyroid cancer (TC), lung cancer (LC), breast invasive carcinoma (BRCA), NB, OS, CESC, OC, glioma, PT, melanoma, oral squamous cell carcinoma, and multiple myeloma, amongst others (25,91-98). Table I lists certain lncRNAs that regulate tumor glycolysis and their identified roles.

*lncRNAs and key glycolytic enzymes regulate tumor glucose metabolism.* It was found that hypoxia inhibited LINC00671 and *STAT3*, the latter of which is a transcription factor regulated by the *STAT3*/LINC00671/LDHA axis, downregulated the production of LDHA, and inhibited the glycolytic and malignant biological activities of TC (99). Non-small cell lung cancer (NSCLC) cells proliferate and undergo glycolysis due to binding and inhibition of miR-507 via LINC00243 through a LINC00243/miR-507/PDK4 axis (34). Additionally, m<sup>6</sup>A methyltransferase-like 3 (*METTL3*) may promote NSCLC

Table I. Regulation of tumor glycolytic-related lncRNAs.

First author, year	Cancer type	lncRNA	Repressed miRNA	Target enzymes involved in glucose metabolism	Potential value	Role	(Refs.)
Liu <i>et al</i> , 2020	Pituitary tumor	UCA1	-	HK2 and LDHA	-	Promotes glycolysis in pituitary cancer cells	(25)
Hong <i>et al</i> , 2021	Glioma cell	LINC01138	miR-375	-	-	Promotes aerobic glycolysis to enhance the biological activity of glioma cells.	(91)
Zhang <i>et al</i> , 2019	Glioblastoma	SNHG9	miR-199a-5p	-	Associated with low survival rates in patients with glioma	Promotes aerobic glycolysis and cell proliferation	(92)
Lu <i>et al</i> , 2020	Glioma cell	SNHG14	-	PKM2 and GLUT1	-	Promotes glycolysis in tumor cells	(93)
Liu <i>et al</i> , 2019	Glioma cell	LINC00689	miR-338-3p	PKM2	-	Promotes glycolysis in tumors	(94)
He <i>et al</i> , 2018	Glioma cells, Glioblastoma-associated stromal cells	UCA1	miR-182	PFKFB2	-	Promotes glycolysis and glioma cell invasion	(95)
Liu <i>et al</i> , 2021	Melanoma	LINC00518	miR-33a-3p	LDHA	Provides a potential way to improve treatment outcomes of melanoma radiotherapy	Promotes tumor glycolysis and reduces sensitivity to melanoma radiotherapy	(96)
Wang <i>et al</i> , 2018	Oral squamous cell carcinoma	Lnc-p23154	miR-378a-3p	GLUT1	-	Promotes the metastasis of tumor cells	(97)
Yang <i>et al</i> , 2018	Multiple myeloma	PDIA3P	-	G6PD	Potential therapeutic target	Promotes tumor cell growth and tolerance to drugs	(98)

UCA1, urothelial cancer associated 1; HK2, hexokinase 2; LDHA, lactate dehydrogenase A; SNHG, small nucleolar RNA host gene; PKM2, pyruvate kinase 2; GLUT1, glucose transporter type 1; PFKFB2, 6-phosphofructose-2-kinase/fructose-2,6-bisphosphatase 2; G6PD, Glucose-6-phosphate dehydrogenase; PDIA3P, protein disulfide isomerase family A member 3 pseudogene 1; lncRNA, long non-coding RNA; miRNA, microRNA.

progression and glucose metabolism by increasing the stability of ABHD11-AS1 (100). Through the LINC00346-miR-148a/b-GLUT1 axis, LINC00346 downregulates miR-148a/b, promoting GLUT1 expression and thus, glycolysis in BRCA cells (35). The expression of glycolysis-related enzymes is critical for the survival of OS cells. The lncRNA plasmacytoma transformation migration gene 1 (PVT1) promotes OS glycolysis and increases HK2 expression through the

binding and inhibition of miR-497 through the miR-497/HK2 axis (101). Furthermore, TUG1 also promotes OS glycolysis by upregulating HK2 expression (102). ALDOA expression is upregulated in the KCNQ10T1/miR-34c-5p/ALDOA axis due to competitive interactions between KCNQ10T1 and miR-34c-5p, which promote OS progression and glucose metabolism (103). The study of CESC found that inhibiting the UCA1/HK2/glycolysis pathway by downregulating

HK2 expression decreased the levels of glycolysis in CESC, increasing the radiosensitivity of CESC cells (26). It was also discovered that HOXB-AS3 functions in OC as a ceRNA to bind and inhibit miR-378A-3P, promoting LDHA expression and enhancing glycolytic, proliferative, and metastatic activities in OC (104).

*lncRNAs and signaling molecules regulate tumor glucose metabolism.* It has been found that acetylserotonin O-methyltransferase like antisense RNA 1 (ASMTL-AS1) upregulates the expression of forkhead box O1 (*FOXO1*) and inhibits glycolysis in papillary thyroid carcinoma (PTC) through an ASMTL-AS1/miR-93-3P/miR-660/*FOXO1* axis. A positive feedback loop created by the recombination of *FOXO1* and ASMTL-AS1 can further inhibit the occurrence and progression of PTC (105). It was also shown that the lncRNA sequence similarity family 83 member A-antisense ribonucleic acid 1 (FAM83A-AS1) upregulated *HIF1A* expression through a *HIF1A*/glycolytic axis to accelerate the progression of lung adenocarcinoma (106). Hepatocyte nuclear factor 4  $\alpha$  antisense RNA 1 (HNF4A-AS1) binds to heterogeneous nuclear ribonucleoprotein U (hnRNP) through an HNF4A-AS1/hnRNP/CCCTC-binding factor (CTCF) axis, which transactivates CTCF upregulates HNF4A expression, and promotes aerobic glycolysis and NB cell invasion (107). To activate Wnt family member 5A (*Wnt5a*)/receptor tyrosine kinase-like orphan receptor 2 (*Ror2*) signaling and promote OS glycolysis and cell proliferation, circPVT1 binds and inhibits miR-423-5p through the circPVT1-miR-423-5p-*Wnt5a/Ror2* axis (108). It was found that LINC00092 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 (PFKFB2) together promoted glycolysis in OC metastasis, which in turn maintained the characteristics of cancer-associated fibroblasts in the tumor microenvironment. In addition, the chemokine CXCL14 promoted OC metastasis *in vivo* and *in vitro*, forming a positive feedback loop that regulated the biological activity of OC (109). The HIPPO pathway regulates cell proliferation and cell invasion. LINC00857 upregulates the expression of the oncogene *YAP1* through a LINC00857/miR-486-5p/*YAP1* axis, which binds to the miR-486-5p pathway, a pathway that inactivates the HIPPO pathway to enhance OC cell proliferation and glycolysis (110). Another study found that LINC00504 promoted the activation of glycolytic enzymes PDK1, PKM2, and HK2 by sponging miR-1244. This enhanced OC cell proliferation and aerobic glycolysis (24). RNA-binding signal transduction-associated protein 3 (KHDRBS3) can promote glycolysis through the gene claudin (*CLDN6*), which is associated with chemoresistance and a key player in several types of cancer. Studies have shown that MIR17HG can inhibit paclitaxel by downregulating the expression of KHDRBS3 and *CLDN6* by targeting the KHDRBS3/MIR17HG/*CLDN6* axis. Paclitaxel cell resistance and glycolysis are novel approaches to treating OC-resistant cells (30).

#### 4. Conclusions and future perspectives

lncRNAs participate in transport, in the activity of key enzymes, in the regulation of miRNAs, in the regulation of various signaling pathways, and in the regulation of tumor

energy metabolism, thus having a broad impact on the malignant properties of cancerous cells. Tumor occurrence and progression are highly correlated with glucose metabolism. Blocking glycolysis or the pentose phosphate pathway can effectively inhibit the proliferation of tumor cells and even result in their death. Therefore, glycolysis-related enzymes may be a novel therapeutic target. However, additional research is required to determine the underlying mechanism of lncRNA regulation of energy metabolism in different types of tumors. For example, it is unknown whether the identified transcription factors and their derived lncRNAs can target and coordinate the regulation of tumor progression. Further research is required to determine how different transcription factors, via lncRNAs, regulate tumor glucose metabolism directly, indirectly, cooperatively, or antagonistically and whether lncRNAs can establish a specific relationship to regulate the expression of tumors jointly. The mechanism of targeted and precise regulation of tumor drug resistance via the interaction between lncRNAs and drugs also needs to be studied. Further research is required to fully understand how different transcription factors regulate tumor expression in the microenvironment under both hypoxic and normoxic conditions. lncRNAs can act as sponges that bind to miRNAs to inhibit the regulatory effect of said miRNAs on their target mRNAs. The discovery of the ceRNA mechanism, which reduces the inhibitory effect of miRNAs on target genes, opens novel avenues for further investigation into the lncRNAs. This review may assist in understanding the molecular mechanisms of tumor energy metabolism regulation and offer a fresh perspective for future studies on tumor diagnosis and targeted therapy.

#### Acknowledgments

Not applicable.

#### Funding

The work was supported by the Natural Science Foundation Project of Xizang Autonomous Region (grant no. XZ202101ZR0074G), the Major Cultivation Project of Xizang Minzu University (grant no. 20MDT02), and the National Innovation and Entrepreneurship Training Program for College Students in 2022 (grant no. 202210695033).

#### Availability of data and materials

Not applicable.

#### Authors' contributions

XH contributed to drafting of the manuscript. ZZ and XC were involved in writing the paper and revising it critically for important intellectual content. XW reviewed and edited the manuscript. All authors have read and approved the final manuscript. Data authentication is not applicable.

#### Ethics approval and consent to participate

Not applicable.



## Patient consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## References

- Ma Y, Yang Y, Wang F, Moyer MP, Wei Q, Zhang P, Yang Z, Liu W, Zhang H, Chen N, *et al*: Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/ $\beta$ -catenin signalling pathway via suppression of activator protein 2 $\alpha$ . *Gut* 65: 1494-1504, 2016.
- Yang X, Xie Z, Lei X and Gan R: Long non-coding RNA GAS5 in human cancer. *Oncol Lett* 20: 2587-2594, 2020.
- Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A and Rinn JL: Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. *Genes Dev* 25: 1915-1927, 2011.
- Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK and Kjems J: Natural RNA circles function as efficient microRNA sponges. *Nature* 495: 384-388, 2013.
- Huang Z, Zhou JK, Peng Y, He W and Huang C: The role of long noncoding RNAs in hepatocellular carcinoma. *Mol Cancer* 19: 77, 2020.
- Chen B, Dragomir MP, Fabris L, Bayraktar R, Knutsen E, Liu X, Tang C, Li Y, Shimura T, Ivkovic TC, *et al*: The long noncoding RNA CCAT2 induces chromosomal instability through BOP1-AURKB signaling. *Gastroenterology* 159: 2146-2162.e33, 2020.
- Ji D, Wang Y, Li H, Sun B and Luo X: Long non-coding RNA LINC00461/miR-149-5p/LRIG2 axis regulates hepatocellular carcinoma progression. *Biochem Biophys Res Commun* 512: 176-181, 2019.
- Gil N and Ulitsky I: Regulation of gene expression by cis-acting long non-coding RNAs. *Nat Rev Genet* 21: 102-117, 2020.
- Shi H, Li K, Feng J, Liu G, Feng Y and Zhang X: LncRNA-DANCR Interferes With miR-125b-5p/HK2 axis to desensitize colon cancer cells to cisplatin via activating anaerobic glycolysis. *Front Oncol* 10: 1034, 2020.
- Dimitrova N, Zamudio JR, Jong RM, Soukup D, Resnick R, Sarma K, Ward AJ, Raj A, Lee JT, Sharp PA and Jacks T: LincRNA-p21 activates p21 in cis to promote Polycomb target gene expression and to enforce the G1/S checkpoint. *Mol Cell* 54: 777-790, 2014.
- Feng J, Ma J, Liu S, Wang J and Chen Y: A noncoding RNA LINC00504 interacts with c-Myc to regulate tumor metabolism in colon cancer. *J Cell Biochem* 120: 14725-14734, 2019.
- Wang Y, Lu JH, Wu QN, Jin Y, Wang DS, Chen YX, Liu J, Luo XJ, Meng Q, Pu HY, *et al*: LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. *Mol Cancer* 18: 174, 2019.
- Gao P, Xia JH, Sipeky C, Dong XM, Zhang Q, Yang Y, Zhang P, Cruz SP, Zhang K, Zhu J, *et al*: Biology and clinical implications of the 19q13 aggressive prostate cancer susceptibility locus. *Cell* 174: 576-589.e18, 2018.
- Bian Z, Zhang J, Li M, Feng Y, Wang X, Zhang J, Yao S, Jin G, Du J, Han W, *et al*: LncRNA-FEZF1-AS1 promotes tumor proliferation and metastasis in colorectal cancer by regulating PKM2 Signaling. *Clin Cancer Res* 24: 4808-4819, 2018.
- Liu PY, Tee AE, Milazzo G, Hannan KM, Maag J, Mondal S, Atmadibrata B, Bartonicek N, Peng H, Ho N, *et al*: The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35. *Nat Commun* 10: 5026, 2019.
- Goodall GJ and Wickramasinghe VO: RNA in cancer. *Nat Rev Cancer* 21: 22-36, 2021.
- Li W, Huang K, Wen F, Cui G, Guo H, He Z and Zhao S: LINC00184 silencing inhibits glycolysis and restores mitochondrial oxidative phosphorylation in esophageal cancer through demethylation of PTEN. *EBioMedicine* 44: 298-310, 2019.
- Hua JT, Ahmed M, Guo H, Zhang Y, Chen S, Soares F, Lu J, Zhou S, Wang M, Li H, *et al*: Risk SNP-Mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19. *Cell* 174: 564-575.e18, 2018.
- Guo W, Dong Z, Liu S, Qiao Y, Kuang G, Guo Y, Shen S and Liang J: Promoter hypermethylation-mediated downregulation of miR-770 and its host gene MEG3, a long non-coding RNA, in the development of gastric cardia adenocarcinoma. *Mol Carcinog* 56: 1924-1934, 2017.
- Ganapathy-Kanniappan S and Geschwind JF: Tumor glycolysis as a target for cancer therapy: Progress and prospects. *Mol Cancer* 12: 152, 2013.
- Warburg O: On the origin of cancer cells. *Science* 123: 309-314, 1956.
- Chen C, Wei M, Wang C, Sun D, Liu P, Zhong X and Yu W: Long noncoding RNA KCNQ10T1 promotes colorectal carcinogenesis by enhancing aerobic glycolysis via hexokinase-2. *Aging (Albany NY)* 12: 11685-11697, 2020.
- Wei L, Sun J, Zhang N, Zheng Y, Wang X, Lv L, Liu J, Xu Y, Shen Y and Yang M: Noncoding RNAs in gastric cancer: Implications for drug resistance. *Mol Cancer* 19: 62, 2020.
- Liu Y, He X, Chen Y and Cao D: Long non-coding RNA LINC00504 regulates the Warburg effect in ovarian cancer through inhibition of miR-1244. *Mol Cell Biochem* 464: 39-50, 2020.
- Liu G, Wang L and Li Y: Inhibition of lncRNA-UCA1 suppresses pituitary cancer cell growth and prolactin (PRL) secretion via attenuating glycolysis pathway. *In Vitro Cell Dev Biol Anim* 56: 642-649, 2020.
- Fan L, Huang C, Li J, Gao T, Lin Z and Yao T: Long non-coding RNA urothelial cancer associated 1 regulates radioresistance via the hexokinase 2/glycolytic pathway in cervical cancer. *Int J Mol Med* 42: 2247-2259, 2018.
- Tang J, Yan T, Bao Y, Shen C, Yu C, Zhu X, Tian X, Guo F, Liang Q, Liu Q, *et al*: LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc. *Nat Commun* 10: 3499, 2019.
- Zhai S, Xu Z, Xie J, Zhang J, Wang X, Peng C, Li H, Chen H, Shen B and Deng X: Epigenetic silencing of LncRNA LINC00261 promotes c-myc-mediated aerobic glycolysis by regulating miR-222-3p/HIPK2/ERK axis and sequestering IGF2BP1. *Oncogene* 40: 277-291, 2021.
- Zhao S, Guan B, Mi Y, Shi D, Wei P, Gu Y, Cai S, Xu Y, Li X, Yan D, *et al*: LncRNA MIR17HG promotes colorectal cancer liver metastasis by mediating a glycolysis-associated positive feedback circuit. *Oncogene* 40: 4709-4724, 2021.
- Wu X, Qiu L, Feng H, Zhang H, Yu H, Du Y, Wu H, Zhu S, Ruan Y and Jiang H: KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer. *Life Sci* 293: 120328, 2022.
- Wu K, Wang Z, Huang Y, Yao L, Kang N, Ge W, Zhang R and He W: LncRNA PTPRG-AS1 facilitates glycolysis and stemness properties of esophageal squamous cell carcinoma cells through miR-599/PDK1 axis. *J Gastroenterol Hepatol* 37: 507-517, 2022.
- Sun L, Li J, Yan W, Yao Z, Wang R, Zhou X, Wu H, Zhang G, Shi T and Chen W: H19 promotes aerobic glycolysis, proliferation, and immune escape of gastric cancer cells through the microRNA-519d-3p/lactate dehydrogenase A axis. *Cancer Sci* 112: 2245-2259, 2021.
- Yu T, Li G, Wang C, Gong G, Wang L, Li C, Chen Y and Wang X: MIR210HG regulates glycolysis, cell proliferation, and metastasis of pancreatic cancer cells through miR-125b-5p/HK2/PKM2 axis. *RNA Biol* 18: 2513-2530, 2021.
- Feng X and Yang S: Long non-coding RNA LINC00243 promotes proliferation and glycolysis in non-small cell lung cancer cells by positively regulating PDK4 through sponging miR-507. *Mol Cell Biochem* 463: 127-136, 2020.
- Li Y, Li H, Wang W, Yu X and Xu Q: LINC00346 regulates glycolysis by modulation of glucose transporter 1 in breast cancer cells. *Mol Cell Probes* 54: 101667, 2020.
- Shi Z, Li G, Li Z, Liu J and Tang Y: TMEM161B-AS1 suppresses proliferation, invasion and glycolysis by targeting miR-23a-3p/HIF1AN signal axis in oesophageal squamous cell carcinoma. *J Cell Mol Med* 25: 6535-6549, 2021.
- Zhang H, Shen X, Xiong S, Peng L, Mai W and Xin L: HEIH promotes malignant progression of gastric cancer by regulating STAT3-Mediated autophagy and glycolysis. *Dis Markers* 2022: 2634526, 2022.
- Chen G, Jiang J, Wang X, Feng K and Ma K: lncENST suppress the warburg effect regulating the tumor progress by the Nkx2-5/ErbB2 Axis in hepatocellular carcinoma. *Comput Math Methods Med* 2021: 6959557, 2021.

39. Cao W, Chen HD, Yu YW, Li N and Chen WQ: Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020. *Chin Med J (Engl)* 134: 783-791, 2021.
40. Vargas RE and Wang W: Significance of long non-coding RNA AGPG for the metabolism of esophageal cancer. *Cancer Commun (Lond)* 40: 313-315, 2020.
41. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC and Lordick F: Gastric cancer. *Lancet* 396: 635-648, 2020.
42. Pei LJ, Sun PJ, Ma K, Guo YY, Wang LY and Liu FD: LncRNA-SNHG7 interferes with miR-34a to de-sensitize gastric cancer cells to cisplatin. *Cancer Biomark* 30: 127-137, 2021.
43. Hu J, Huang L, Ding Q, Lv J and Chen Z: Long noncoding RNA HAGLR sponges miR-338-3p to promote 5-Fu resistance in gastric cancer through targeting the LDHA-glycolysis pathway. *Cell Biol Int* 46: 173-184, 2022.
44. Qian Y, Song W, Wu X, Hou G, Wang H, Hang X and Xia T: DLX6 Antisense RNA 1 modulates glucose metabolism and cell growth in gastric cancer by targeting microRNA-4290. *Dig Dis Sci* 66: 460-473, 2021.
45. Deng P, Li K, Gu F, Zhang T, Zhao W, Sun M and Hou B: LINC00242/miR-1-3p/G6PD axis regulates Warburg effect and affects gastric cancer proliferation and apoptosis. *Mol Med* 27: 9, 2021.
46. Dai T, Zhang X, Zhou X, Hu X, Huang X, Xing F, Tian H and Li Y: Long non-coding RNA VAL facilitates PKM2 enzymatic activity to promote glycolysis and malignancy of gastric cancer. *Clin Transl Med* 12: e1088, 2022.
47. Jin X, Qiao L, Fan H, Liao C, Zheng J, Wang W, Ma X, Yang M, Sun X and Zhao W: Long non-coding RNA MSC-AS1 facilitates the proliferation and glycolysis of gastric cancer cells by regulating PFKFB3 expression. *Int J Med Sci* 18: 546-554, 2021.
48. Xu Z, Lv H, Wang Y, Hu C, Chen S, Du Y, Shi C and Cheng X: HAND2-AS1 inhibits gastric adenocarcinoma cells proliferation and aerobic glycolysis via miRNAs Sponge. *Cancer Manag Res* 12: 3053-3068, 2020.
49. Qian C, Xu Z, Chen L, Wang Y and Yao J: Long noncoding RNA LINC01391 restrained gastric cancer aerobic glycolysis and tumorigenesis via targeting miR-12116/CMTM2 axis. *J Cancer* 11: 6264-6276, 2020.
50. Yan B, Ren Z, Sun J, Ding C and Yang D: IGF2-AS knock-down inhibits glycolysis and accelerates apoptosis of gastric cancer cells through targeting miR-195/CREB1 axis. *Biomed Pharmacother* 130: 110600, 2020.
51. Tan HY, Wang C, Liu G and Zhou X: Long noncoding RNA NEAT1-modulated miR-506 regulates gastric cancer development through targeting STAT3. *J Cell Biochem* 120: 4827-4836, 2019.
52. Sun K, Hu P and Xu F: LINC00152/miR-139-5p regulates gastric cancer cell aerobic glycolysis by targeting PRKAA1. *Biomed Pharmacother* 97: 1296-1302, 2018.
53. Li M, Cai O, Yu Y and Tan S: Paeonol inhibits the malignancy of Apatinib-resistant gastric cancer cells via LINC00665/miR-665/MAPK1 axis. *Phytomedicine* 96: 153903, 2022.
54. Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M and Negri E: Global trends and predictions in hepatocellular carcinoma mortality. *J Hepatol* 67: 302-309, 2017.
55. Wang Y, Yang F, Peng Q, Mei K, He H and Yang Q: Long non-coding RNA SNHG1 activates glycolysis to promote hepatocellular cancer progression through the miR-326/PKM2 axis. *J Gene Med* 24: e3440, 2022.
56. Guan YF, Huang QL, Ai YL, Chen QT, Zhao WX, Wang XM, Wu Q and Chen HZ: Nur77-activated lncRNA WFDC21P attenuates hepatocarcinogenesis via modulating glycolysis. *Oncogene* 39: 2408-2423, 2020.
57. Wang C, Li Y, Yan S, Wang H, Shao X, Xiao M, Yang B, Qin G, Kong R, Chen R and Zhang N: Interactome analysis reveals that lncRNA HULC promotes aerobic glycolysis through LDHA and PKM2. *Nat Commun* 11: 3162, 2020.
58. Shang R, Wang M, Dai B, Du J, Wang J, Liu Z, Qu S, Yang X, Liu J, Xia C, *et al*: Long noncoding RNA SLC2A1-AS1 regulates aerobic glycolysis and progression in hepatocellular carcinoma via inhibiting the STAT3/FOXO1/GLUT1 pathway. *Mol Oncol* 14: 1381-1396, 2020.
59. Lin YH, Wu MH, Huang YH, Yeh CT, Cheng ML, Chi HC, Tsai CY, Chung IH, Chen CY and Lin KH: Taurine up-regulated gene 1 functions as a master regulator to coordinate glycolysis and metastasis in hepatocellular carcinoma. *Hepatology* 67: 188-203, 2018.
60. Li S, Li J, Dai W, Zhang Q, Feng J, Wu L, Liu T, Yu Q, Xu S, Wang W, *et al*: Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death. *Br J Cancer* 117: 1518-1528, 2017.
61. Li S, Dai W, Mo W, Li J, Feng J, Wu L, Liu T, Yu Q, Xu S, Wang W, *et al*: By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma. *Int J Cancer* 141: 2571-2584, 2017.
62. Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu D, Fodstad O and Tan M: Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. *Oncogene* 28: 3689-3701, 2009.
63. Hu M, Fu Q, Jing C, Zhang X, Qin T and Pan Y: LncRNA HOTAIR knockdown inhibits glycolysis by regulating miR-130a-3p/HIF1A in hepatocellular carcinoma under hypoxia. *Biomed Pharmacother* 125: 109703, 2020.
64. Li Y, Guo D, Zhao Y, Ren M, Lu G, Wang Y, Zhang J, Mi C, He S and Lu X: Long non-coding RNA SNHG5 promotes human hepatocellular carcinoma progression by regulating miR-26a-5p/GSK3 $\beta$  signal pathway. *Cell Death Dis* 9: 888, 2018.
65. Huang Y, Xiang B, Liu Y, Wang Y and Kan H: LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis. *Cancer Lett* 437: 56-66, 2018.
66. Zhang H, Su X, Burley SK and Zheng XFS: mTOR regulates aerobic glycolysis through NEAT1 and nuclear paraspeckle-mediated mechanism in hepatocellular carcinoma. *Theranostics* 12: 3518-3533, 2022.
67. He H, Chen T, Mo H, Chen S, Liu Q and Guo C: Hypoxia-inducible long noncoding RNA NPSR1-AS1 promotes the proliferation and glycolysis of hepatocellular carcinoma cells by regulating the MAPK/ERK pathway. *Biochem Biophys Res Commun* 533: 886-892, 2020.
68. Li X, Zhao Q, Qi J, Wang W, Zhang D, Li Z and Qin C: lncRNA Ftx promotes aerobic glycolysis and tumor progression through the PPAR $\gamma$  pathway in hepatocellular carcinoma. *Int J Oncol* 53: 551-566, 2018.
69. Ma X, Mao Z, Zhu J, Liu H and Chen F: lncRNA PANTR1 Upregulates BCL2A1 expression to promote tumorigenesis and warburg effect of hepatocellular carcinoma through restraining miR-587. *J Immunol Res* 2021: 1736819, 2021.
70. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. *CA Cancer J Clin* 69: 7-34, 2019.
71. Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W and Palmer DH: Therapeutic developments in pancreatic cancer: Current and future perspectives. *Nat Rev Gastroenterol Hepatol* 15: 333-348, 2018.
72. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res* 74: 2913-2921, 2014.
73. Xu F, Huang M, Chen Q, Niu Y, Hu Y, Hu P, Chen D, He C, Huang K, Zeng Z, *et al*: LncRNA HIF1A-AS1 promotes gemcitabine resistance of pancreatic cancer by enhancing glycolysis through modulating the AKT/YB1/HIF1 $\alpha$  pathway. *Cancer Res* 81: 5678-5691, 2021.
74. Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, Kramer J and Siegel RL: Cancer treatment and survivorship statistics, 2022. *CA Cancer J Clin* 72: 409-436, 2022.
75. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 68: 394-424, 2018.
76. Wu C, Li M, Meng H, Liu Y, Niu W, Zhou Y, Zhao R, Duan Y, Zeng Z, Li X, *et al*: Analysis of status and countermeasures of cancer incidence and mortality in China. *Sci China Life Sci* 62: 640-647, 2019.
77. Yan T, Shen C, Jiang P, Yu C, Guo F, Tian X, Zhu X, Lu S, Han B, Zhong M, *et al*: Risk SNP-induced lncRNA-SLCC1 drives colorectal cancer through activating glycolysis signaling. *Signal Transduct Target Ther* 6: 70, 2021.
78. Huang JZ, Chen M, Chen D, Gao XC, Zhu S, Huang H, Hu M, Zhu H and Yan GR: A peptide encoded by a putative lncRNA HOXB-AS3 suppresses colon cancer growth. *Mol Cell* 68: 171-184.e6, 2017.
79. Li S, Zhu K, Liu L, Gu J, Niu H and Guo J: lncARSR sponges miR-34a-5p to promote colorectal cancer invasion and metastasis via hexokinase-1-mediated glycolysis. *Cancer Sci* 111: 3938-3952, 2020.

80. Lan Z, Yao X, Sun K, Li A, Liu S and Wang X: The interaction between lncRNA SNHG6 and hnRNP A1 contributes to the growth of colorectal cancer by enhancing aerobic glycolysis through the regulation of alternative splicing of PKM. *Front Oncol* 10: 363, 2020.
81. Zheng H, Zhang M, Ke X, Deng X, Li D, Wang Q, Yan S, Xue Y and Wang Q: LncRNA XIST/miR-137 axis strengthens chemo-resistance and glycolysis of colorectal cancer cells by hindering transformation from PKM2 to PKM1. *Cancer Biomark* 30: 395-406, 2021.
82. Cui K, Wu H, Fan J, Zhang L, Li H, Guo H, Yang R and Li Z: The mixture of ferulic acid and P-Coumaric acid suppresses colorectal cancer through lncRNA 495810/PKM2 mediated aerobic glycolysis. *Int J Mol Sci* 23: 12106, 2022.
83. Wang Y, Yu G, Liu Y, Xie L, Ge J, Zhao G and Lin J: Hypoxia-induced PTTG3P contributes to colorectal cancer glycolysis and M2 phenotype of macrophage. *Biosci Rep* 41: BSR20210764, 2021.
84. Sun S, Li W, Ma X and Luan H: Long Noncoding RNA LINC00265 promotes glycolysis and lactate production of colorectal cancer through regulating of miR-216b-5p/TRIM44 Axis. *Digestion* 101: 391-400, 2020.
85. Yu Z, Wang Y, Deng J, Liu D, Zhang L, Shao H, Wang Z, Zhu W, Zhao C and Ke Q: Long non-coding RNA COL4A2-AS1 facilitates cell proliferation and glycolysis of colorectal cancer cells via miR-20b-5p/hypoxia inducible factor 1 alpha subunit axis. *Bioengineered* 12: 6251-6263, 2021.
86. Li C, Wang P, Du J, Chen J, Liu W and Ye K: LncRNA RAD51-AS1/miR-29b/c-3p/NDRG2 crosstalk repressed proliferation, invasion and glycolysis of colorectal cancer. *IUBMB Life* 73: 286-298, 2021.
87. Zhang Z, Yang W, Li N, Chen X, Ma F, Yang J, Zhang Y, Chai X, Zhang B, Hou X, *et al*: LncRNA MCF2L-AS1 aggravates proliferation, invasion and glycolysis of colorectal cancer cells via the crosstalk with miR-874-3p/FOXO1 signaling axis. *Carcinogenesis* 42: 263-271, 2021.
88. Guo X, Zhang Y, Liu L, Yang W and Zhang Q: HNF1A-AS1 regulates cell migration, invasion and glycolysis via modulating miR-124/MYO6 in colorectal cancer cells. *Onco Targets Ther* 13: 1507-1518, 2020.
89. Li YL, Zhang XX, Yao JN, Gao B, Gao SL, Wang CF, Zhou HN and Zhang LF: ZEB2-AS1 regulates the expression of TAB3 and promotes the development of colon cancer by adsorbing microRNA-188. *Eur Rev Med Pharmacol Sci* 24: 4180-4189, 2020.
90. Wang X, Zhang H, Yin S, Yang Y, Yang H, Yang J, Zhou Z, Li S, Ying G and Ba Y: lncRNA-encoded pep-AP attenuates the pentose phosphate pathway and sensitizes colorectal cancer cells to Oxaliplatin. *EMBO Rep* 23: e53140, 2022.
91. Hong J, Guo F, Lu SY, Shen C, Ma D, Zhang X, Xie Y, Yan T, Yu T, Sun T, *et al*: F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer. *Gut* 70: 2123-2137, 2021.
92. Zhang H, Qin D, Jiang Z and Zhang J: SNHG9/miR-199a-5p/Wnt2 axis regulates cell growth and aerobic glycolysis in glioblastoma. *J Neuropathol Exp Neurol* 78: 939-948, 2019.
93. Lu J, Liu X, Zheng J, Song J, Liu Y, Ruan X, Shen S, Shao L, Yang C, Wang D, *et al*: Lin28A promotes IRF6-regulated aerobic glycolysis in glioma cells by stabilizing SNHG14. *Cell Death Dis* 11: 447, 2020.
94. Liu X, Zhu Q, Guo Y, Xiao Z, Hu L and Xu Q: LncRNA LINC00689 promotes the growth, metastasis and glycolysis of glioma cells by targeting miR-338-3p/PKM2 axis. *Biomed Pharmacother* 117: 109069, 2019.
95. He Z, You C and Zhao D: Long non-coding RNA UCA1/miR-182/PFKFB2 axis modulates glioblastoma-associated stromal cells-mediated glycolysis and invasion of glioma cells. *Biochem Biophys Res Commun* 500: 569-576, 2018.
96. Liu Y, He D, Xiao M, Zhu Y, Zhou J and Cao K: Long noncoding RNA LINC00518 induces radioresistance by regulating glycolysis through an miR-33a-3p/HIF-1 $\alpha$  negative feedback loop in melanoma. *Cell Death Dis* 12: 245, 2021.
97. Wang Y, Zhang X, Wang Z, Hu Q, Wu J, Li Y, Ren X, Wu T, Tao X, Chen X, *et al*: LncRNA-p23154 promotes the invasion-metastasis potential of oral squamous cell carcinoma by regulating Glut1-mediated glycolysis. *Cancer Lett* 434: 172-183, 2018.
98. Yang X, Ye H, He M, Zhou X, Sun N, Guo W, Lin X, Huang H, Lin Y, Yao R and Wang H: LncRNA PDIA3P interacts with c-Myc to regulate cell proliferation via induction of pentose phosphate pathway in multiple myeloma. *Biochem Biophys Res Commun* 498: 207-213, 2018.
99. Huo N, Cong R, Sun ZJ, Li WC, Zhu X, Xue CY, Chen Z, Ma LY, Chu Z, Han YC, *et al*: STAT3/LINC00671 axis regulates papillary thyroid tumor growth and metastasis via LDHA-mediated glycolysis. *Cell Death Dis* 12: 799, 2021.
100. Xue L, Li J, Lin Y, Liu D, Yang Q, Jian J and Peng J: m6 A transferase METTL3-induced lncRNA ABHD11-AS1 promotes the Warburg effect of non-small-cell lung cancer. *J Cell Physiol* 236: 2649-2658, 2021.
101. Song J, Wu X, Liu F, Li M, Sun Y, Wang Y, Wang C, Zhu K, Jia X, Wang B and Ma X: Long non-coding RNA PVT1 promotes glycolysis and tumor progression by regulating miR-497/HK2 axis in osteosarcoma. *Biochem Biophys Res Commun* 490: 217-224, 2017.
102. Han X, Yang Y, Sun Y, Qin L and Yang Y: LncRNA TUG1 affects cell viability by regulating glycolysis in osteosarcoma cells. *Gene* 674: 87-92, 2018.
103. Shen Y, Xu J, Pan X, Zhang Y, Weng Y, Zhou D and He S: LncRNA KCNQ1OT1 sponges miR-34c-5p to promote osteosarcoma growth via ALDOA enhanced aerobic glycolysis. *Cell Death Dis* 11: 278, 2020.
104. Xu S, Jia G, Zhang H, Wang L, Cong Y, Lv M, Xu J, Ruan H, Jia X, Xu P and Wang Y: LncRNA HOXB-AS3 promotes growth, invasion and migration of epithelial ovarian cancer by altering glycolysis. *Life Sci* 264: 118636, 2021.
105. Feng Z, Chen R, Huang N and Luo C: Long non-coding RNA ASMTL-AS1 inhibits tumor growth and glycolysis by regulating the miR-93-3p/miR-660/FOXO1 axis in papillary thyroid carcinoma. *Life Sci* 244: 117298, 2020.
106. Chen Z, Hu Z, Sui Q, Huang Y, Zhao M, Li M, Liang J, Lu T, Zhan C, Lin Z, *et al*: LncRNA FAM83A-AS1 facilitates tumor proliferation and the migration via the HIF-1 $\alpha$ /glycolysis axis in lung adenocarcinoma. *Int J Biol Sci* 18: 522-535, 2022.
107. Song H, Li D, Wang X, Fang E, Yang F, Hu A, Wang J, Guo Y, Liu Y, Li H, *et al*: HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression. *J Hematol Oncol* 13: 24, 2020.
108. Wan J, Liu Y, Long F, Tian J and Zhang C: circPVT1 promotes osteosarcoma glycolysis and metastasis by sponging miR-423-5p to activate Wnt5a/Ror2 signaling. *Cancer Sci* 112: 1707-1722, 2021.
109. Zhao L, Ji G, Le X, Wang C, Xu L, Feng M, Zhang Y, Yang H, Xuan Y, Yang Y, *et al*: Long Noncoding RNA LINC00092 acts in cancer-associated fibroblasts to drive glycolysis and progression of ovarian cancer. *Cancer Res* 77: 1369-1382, 2017.
110. Lin X, Feng D, Li P and Lv Y: LncRNA LINC00857 regulates the progression and glycolysis in ovarian cancer by modulating the Hippo signaling pathway. *Cancer Med* 9: 8122-8132, 2020.



Copyright © 2023 Hou et al. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.